公开(公告)号：US20200262860A1

公开(公告)日：2020-08-20

申请号：US16851217

申请日：2020-04-17

Applicant: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Inventor： Hong Ye ,  Gang Liu ,  Nan Yu ,  Hong Zeng ,  Mingliang Zhao ,  Yan Qing ,  Hua Deng ,  Wenjia Li ,  Donghong Li ,  Donghai Su ,  Wei Zhong ,  Shaohua Li ,  Xunwei Wu ,  Lichun Wang ,  Jingyi Wang

IPC: C07H19/10 ,  A61K45/06 ,  A61K31/7076 ,  A61K31/7068 ,  C07H1/00 ,  C07H19/20

Abstract: The present application relates to a method for the prevention or treatment of an abnormal cell proliferative disease in a mammal, wherein the method comprises administering to the mammal an effective amount of a 4′-thionucleoside compound or a pharmaceutically acceptable salt, ester, hydrate, solvate thereof, or racemate thereof, or a mixture thereof.

公开(公告)号：US20180305464A1

公开(公告)日：2018-10-25

申请号：US15745230

申请日：2017-03-02

Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO.,LTD

Inventor： Baiyong Li ,  Tongtong Xue ,  Yu Xia ,  Zhongmin Maxwell Wang ,  Liang Xiao ,  Lichun Wang ,  Jingyi Wang

IPC: C07K16/46 ,  C07K16/28 ,  A61P35/02 ,  A61K47/68

Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.